SI1509618T1 - Avtoimunska stanja in defekti NADPH oksidaze - Google Patents

Avtoimunska stanja in defekti NADPH oksidaze

Info

Publication number
SI1509618T1
SI1509618T1 SI200331420T SI200331420T SI1509618T1 SI 1509618 T1 SI1509618 T1 SI 1509618T1 SI 200331420 T SI200331420 T SI 200331420T SI 200331420 T SI200331420 T SI 200331420T SI 1509618 T1 SI1509618 T1 SI 1509618T1
Authority
SI
Slovenia
Prior art keywords
nadph oxidase
methods
autoimmune conditions
materials involved
conditions
Prior art date
Application number
SI200331420T
Other languages
English (en)
Inventor
Rikard Holmdahl
Peter Olofsson
Original Assignee
Arexis Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arexis Ab filed Critical Arexis Ab
Publication of SI1509618T1 publication Critical patent/SI1509618T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90209—Oxidoreductases (1.) acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Rehabilitation Therapy (AREA)
  • Neurology (AREA)
SI200331420T 2002-05-13 2003-05-13 Avtoimunska stanja in defekti NADPH oksidaze SI1509618T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38090402P 2002-05-13 2002-05-13
US42960902P 2002-11-27 2002-11-27
EP03727901A EP1509618B1 (en) 2002-05-13 2003-05-13 Autoimmune conditions and nadph oxidase defects
PCT/IB2003/002419 WO2003095667A2 (en) 2002-05-13 2003-05-13 Autoimmune conditions and nadph oxidase defects

Publications (1)

Publication Number Publication Date
SI1509618T1 true SI1509618T1 (sl) 2009-02-28

Family

ID=29423757

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331420T SI1509618T1 (sl) 2002-05-13 2003-05-13 Avtoimunska stanja in defekti NADPH oksidaze

Country Status (13)

Country Link
US (3) US7294652B2 (sl)
EP (1) EP1509618B1 (sl)
JP (1) JP4578235B2 (sl)
AT (1) ATE405670T1 (sl)
AU (1) AU2003233147B2 (sl)
CA (1) CA2483105C (sl)
CY (1) CY1108580T1 (sl)
DE (1) DE60323091D1 (sl)
DK (1) DK1509618T3 (sl)
ES (1) ES2312780T3 (sl)
PT (1) PT1509618E (sl)
SI (1) SI1509618T1 (sl)
WO (1) WO2003095667A2 (sl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU782966B2 (en) 1999-06-08 2005-09-15 University Of Iowa Research Foundation, The Compounds and methods to enhance RAAV transduction
EP1509618B1 (en) 2002-05-13 2008-08-20 Arexis AB Autoimmune conditions and nadph oxidase defects
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
EP1602926A1 (en) 2004-06-04 2005-12-07 University of Geneva Novel means and methods for the treatment of hearing loss and phantom hearing
US7825099B2 (en) * 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US20080051451A1 (en) * 2006-03-15 2008-02-28 Marcel Linschoten Autoimmune conditions and NADPH oxidase defects
AU2007224438B2 (en) * 2006-03-15 2012-07-26 Biovitrum Ab (Publ) Autoimmune conditions and NADPH oxidase defects
WO2007127464A2 (en) * 2006-04-28 2007-11-08 University Of Iowa Research Foundation Methods and compounds to modulate parvovirus transduction of mammalian cells or to alter virus infection, method to identify a viral receptor or co-receptor
KR101252001B1 (ko) * 2006-06-15 2013-04-08 삼성디스플레이 주식회사 액정 표시 장치 및 그 제조 방법
WO2008152636A2 (en) * 2007-06-15 2008-12-18 Quark Pharmaceuticals, Inc. Compositions and methods for inhibiting nadph oxidase expression
PT2391653E (pt) * 2009-01-28 2015-02-13 Ind Tech Res Inst Biomarcadores associados a nefropatia
GB201104600D0 (en) 2011-03-18 2011-05-04 Pronoxis Ab New compounds and medical uses
US11702672B2 (en) 2016-02-08 2023-07-18 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
CA3016985C (en) 2016-03-07 2023-07-04 University Of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
KR102030127B1 (ko) * 2019-01-10 2019-10-08 주식회사 보타닉센스 운데칸 또는 운데칸알을 유효성분으로 포함하는 항알러지, 아토피 피부염 개선, 또는 피부 재생용 조성물
WO2021167123A1 (ko) * 2020-02-18 2021-08-26 연세대학교 산학협력단 탄소수 14 내지 17의 직쇄 알칸을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소증 억제효과를 갖는 조성물
CN113607714B (zh) * 2021-10-08 2022-01-11 成都齐碳科技有限公司 分子膜成膜或表征器件、装置、方法以及生物芯片
CN114916501B (zh) * 2022-05-16 2023-01-31 四川大学华西医院 二亚苯基碘鎓氯化物用于类风湿关节炎模型造模的用途、类风湿关节炎模型造模方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3734952A (en) 1968-12-27 1973-05-22 Hoffmann La Roche Preparation of l-dopa
US5280048A (en) * 1982-05-28 1994-01-18 Eisai Co., Ltd. β,γ-dihydropolyprenyl alcohol derivatives and pharmaceutical composition containing a polyprenyl compound
JPS61257944A (ja) 1986-03-20 1986-11-15 Nisshin Flour Milling Co Ltd 潰瘍治療剤
US4983637A (en) 1988-06-24 1991-01-08 Stephen Herman Method for treating viral infection of HIV
DE3829641A1 (de) * 1988-09-01 1990-03-15 Roecar Holdings Nv Transdermal anwendbare pharmazeutische zubereitungen mit sterolinen und/oder spiroketalinen
RU1827623C (ru) * 1990-01-30 1993-07-15 Ленинградский педиатрический медицинский институт Способ прогнозировани осложнений тимэктомии у больных миастенией
US5602184A (en) 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
US5475029A (en) * 1993-07-08 1995-12-12 The Board Of Trustees Of The Leland Stanford Junior University Farnesyl compounds as cholesterol lowering agents
GB2285047B (en) 1993-12-21 1998-04-15 Yamanouchi U K Ltd Polypeptides which inhibit the NADPH oxidase complex
US5763496A (en) * 1995-11-27 1998-06-09 The Research Foundation Of State University Of New York Prevention of atherosclerosis using NADPH oxidase inhibitors
US5939460A (en) 1996-07-08 1999-08-17 Idun Pharmaceuticals, Inc. Method of inhibiting NADPH oxidase
AU3444297A (en) * 1996-07-12 1998-02-09 Novartis Consumer Health S.A. Oral pharmaceutical combinations of nsaids with terpenoids
DE19644422C2 (de) 1996-10-25 2000-06-15 Stefan Schulz Verwendung von Terpenen zur Behandlung von Autoimmunkrankheiten und bei Transplantat-Abstoßungsreaktionen
JPH10168090A (ja) 1996-12-11 1998-06-23 Eisai Co Ltd アポトーシス誘導剤
AU9226198A (en) 1997-09-10 1999-03-29 Johns Hopkins University School Of Medicine, The The use of an nadph-oxidase inhibitor in the treatment of reperfusion injury
US6034659A (en) * 1998-02-02 2000-03-07 Wald; Steven F. Active matrix electroluminescent grey scale display
US20030190368A1 (en) * 1998-03-11 2003-10-09 Roland Stoughton Methods of diagnosis and triage using cell activation measures
US6242473B1 (en) 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6602698B2 (en) 1999-12-07 2003-08-05 Lexicon Genetics Incorporated Human kinase proteins and polynucleotides encoding the same
JP2001172171A (ja) 1999-10-06 2001-06-26 Kazuhito Rokutan 熱ショック蛋白質誘導剤
WO2001042453A1 (fr) 1999-12-06 2001-06-14 Biomolecular Engineering Research Institute Coordonnees structurales et decalage chimique rmn de proteine; utilisation
IL142535A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
IL142537A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of autoimmune diseases
IL142536A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
EP1509618B1 (en) 2002-05-13 2008-08-20 Arexis AB Autoimmune conditions and nadph oxidase defects
AU2005329255B2 (en) * 2004-04-15 2010-09-30 Chiasma, Inc. Compositions capable of facilitating penetration across a biological barrier
FR2869230B1 (fr) 2004-04-23 2006-07-28 Alessio Patrizia D Composition pour prevenir ou traiter la degenerescence cellulaire en utilisant au moins une molecule capable de maintenir la reversibilite de l'expression des molecules d'adherence et la polymerisation des fibres d'actine

Also Published As

Publication number Publication date
DE60323091D1 (de) 2008-10-02
ATE405670T1 (de) 2008-09-15
ES2312780T3 (es) 2009-03-01
JP2005525122A (ja) 2005-08-25
PT1509618E (pt) 2008-12-02
JP4578235B2 (ja) 2010-11-10
WO2003095667A3 (en) 2004-12-02
DK1509618T3 (da) 2008-12-08
EP1509618A2 (en) 2005-03-02
EP1509618B1 (en) 2008-08-20
AU2003233147A1 (en) 2003-11-11
AU2003233147B2 (en) 2008-03-06
US20040009901A1 (en) 2004-01-15
CY1108580T1 (el) 2014-04-09
CA2483105C (en) 2011-05-10
CA2483105A1 (en) 2003-11-20
US20100227354A1 (en) 2010-09-09
US7943338B2 (en) 2011-05-17
US7294652B2 (en) 2007-11-13
WO2003095667A2 (en) 2003-11-20
US20080227135A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
CY1108580T1 (el) Αυτοανοσες παθησεις και ελλειμματα nadph οξειδασης
HK1069767A1 (en) Methods for inhibiting ocular processes
SG161286A1 (en) Methods for treating and preventing fibrosis by il-21 / il-21r antagonists
WO2006034235A3 (en) Substituted quinoline and quinazoline inhibitors of quinone reductase 2
TW200531679A (en) Methods of modulating cytokine activity; related reagents
WO2004052348A3 (en) Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
EP1461061A4 (en) COMPOSITIONS AND METHODS FOR THE DETECTION AND TREATMENT OF DISEASES AND CONDITIONS RELATED TO CHEMOKINE RECEPTORS
IL166241A0 (en) Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
WO2003104410A3 (en) ENZYMES
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
IL179441A (en) Method of measuring the activity of egln enzyme and of identifying an agent that modulates activity of said enzyme
AU8691801A (en) Erbb4 antagonists
EP2101772A4 (en) NEUROMUSCULAR BLOCKAGE AGENTS WITH INTERMEDIATE DURATION AND THEIR ANTAGONISTS
WO2003063795A3 (en) Compositions and methods for treating diarrhea
MX2007010332A (es) Metodos y composiciones para promover adhesion o migracion de celula endotelial.
WO2005072290A3 (en) Methods of treating, reducing, or preventing autoimmune conditions
WO2004108887A3 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
EP1601687A4 (en) METHOD FOR INCREASING THE SPREAD OF B-CELLS
MY131027A (en) Methods for predicting board test coverage
WO2004045545A3 (en) Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
WO2005113789A3 (en) Method for identifying compounds that have the ability to inhibit the activity of myc
AU2003293556A1 (en) Methods of diagnosing and treating cancer
WO2004041197A3 (en) Methods of inhibiting glial scar formation
WO2004112729A8 (en) Dual function compounds and uses thereof
WO2007065124A3 (en) Methods of identifying and treating individuals exhibiting complex karyotypes